Stemline Therapeutics (STML) a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics.
STML develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.
STML also develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development.
Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
- September 11, 2018 - 1:18pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q2
- June 2, 2018 - 7:11am | Out and About, Out and About, Earnings, Earnings Q1
- March 10, 2018 - 9:22am | Earnings, Earnings Q4
- March 4, 2018 - 11:11am | Analysis, Out and About
- January 22, 2018 - 5:00pm | Out and About, Financings
- November 3, 2017 - 1:08pm | Earnings, Earnings Q3
- May 5, 2017 - 8:59am | Earnings, Earnings Q1
- March 10, 2017 - 12:00am | Earnings, Earnings Q4
- February 7, 2017 - 12:42pm | Research Notes
- January 19, 2017 - 4:54pm | Research Notes, Financings
- November 2, 2016 - 8:46pm | Earnings, Earnings Q3
- August 23, 2016 - 8:42am | Research Notes
- August 4, 2016 - 10:50pm | Earnings, Earnings Q2
- December 7, 2015 - 11:44am | Research Notes
- November 16, 2015 - 10:34am | Earnings Q3
- November 2, 2015 - 8:16am | Regulatory
- September 10, 2015 - 8:39am | Research Notes, Regulatory
- March 24, 2015 - 9:13am | BOD & C-Suite Updates
- January 30, 2015 - 9:13am | Regulatory
- January 8, 2015 - 9:25am | Financings